Publicaciones en colaboración con investigadores/as de Imperial College London (40)

2024

  1. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)

    Transplantation and Cellular Therapy, Vol. 30, Núm. 1, pp. 93.e1-93.e12

  2. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee

    eClinicalMedicine, Vol. 69

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study

    European Urology Focus, Vol. 8, Núm. 6, pp. 1673-1682

  2. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

    American Journal of Hematology

  3. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: Final results of the SYNTAX II study

    European Heart Journal, Vol. 43, Núm. 13, pp. 1307-1316

  4. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study

    Liver International, Vol. 42, Núm. 8, pp. 1891-1901

2021

  1. Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function

    Translational Psychiatry, Vol. 11, Núm. 1

  2. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

    BMC Infectious Diseases, Vol. 21, Núm. 1

  3. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

    Leukemia, Vol. 35, Núm. 10, pp. 2885-2894

  4. Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function (Translational Psychiatry, (2021), 11, 1, (579), 10.1038/s41398-021-01705-z)

    Translational Psychiatry

  5. Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis

    The Lancet Psychiatry, Vol. 8, Núm. 7, pp. 589-598

  6. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

    American Journal of Hematology, Vol. 96, Núm. 6, pp. 708-718

  7. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

    Journal of Hematology and Oncology

  8. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

    American Journal of Hematology, Vol. 96, Núm. 9, pp. 1120-1130

  9. The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer – a multicentre observational study

    BJU International, Vol. 128, Núm. 4, pp. 440-450

  10. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

    New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802

2020

  1. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

    Bone Marrow Transplantation, Vol. 55, Núm. 2, pp. 283-306

  2. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573

  3. Tricuspid regurgitation severity after atrial septal defect closure or pulmonic valve replacement

    Heart, Vol. 106, Núm. 6, pp. 455-461